A Prospective Feasibility Study of a 1-mm bolus for Postmastectomy Radiotherapy

Terufumi Kawamoto (t-kawamoto@juntendo.ac.jp)  Juntendo Daigaku  https://orcid.org/0000-0001-9014-5577
Naoto Shikama  Juntendo Daigaku
Chie Kurokawa  Juntendo Daigaku
Naoya Hara  Juntendo Daigaku
Masaki Oshima  Juntendo Daigaku
Keisuke Sasai  Juntendo Daigaku

Research article

Keywords: Bolus, breast cancer, dosimetry analysis, postmastectomy radiotherapy

Posted Date: December 21st, 2020

DOI: https://doi.org/10.21203/rs.3.rs-130273/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on February 2nd, 2021. See the published version at https://doi.org/10.1186/s12885-021-07851-3.
Abstract

Background: The optimal chest wall bolus regimen for postmastectomy radiotherapy (PMRT) remains unknown. We aimed to prospectively evaluate the use of a 1-mm-thick daily tissue-equivalent bolus in patients who received PMRT using thermoluminescent dosimeters (TLDs) and skin toxicity assessment.

Methods: Patients with a 1-mm-thick daily bolus during PMRT were prospectively enrolled at The Juntendo University Hospital. The surface dose was measured in vivo under the 1-mm-thick bolus on the chest wall. We assessed the acute skin toxicity weekly during PMRT, and 1, 2, 4, and 12 weeks after the completion of PMRT.

Results: A total of 19 patients aged 32–79 years old received PMRT from July 2019 to January 2020. All patients completed the protocol treatment without interruptions, and the median follow-up was 32 weeks. In vivo dosimetry analysis revealed surface doses between 77% and 113% of the prescribed dose, with a mean of 92% of the prescribed radiation dose, and a standard deviation of 7% being delivered. Grade 2 dermatitis was found in 10 patients (53%), and Grade 3 dermatitis was found in one patient (5%). All cases of Grade 2 and 3 dermatitis were improved 4 weeks after PMRT. There were no cases of Grade 4 dermatitis and no chest wall recurrences during the treatment or follow-up period.

Conclusions: The results confirmed the feasibility of using the 1-mm-thick daily bolus for PMRT, with appropriate dose buildup and acceptable skin toxicity without treatment interruptions.

Trial registration: The University Hospital Medical Information Network Clinical Trials Registry, UMIN000035773. Registered 1 July 2019, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040622

Background

Postmastectomy radiotherapy (PMRT) has been proven to increase both locoregional control and overall survival among high-risk breast cancer patients [1–4]. However, there is currently various regimen regarding the bolus regimen and bolus material for PMRT.

Tissue-equivalent materials are applied to the chest wall to provide dose buildup in the skin and tissue in order to adequately deliver the prescription dose to the level of skin and treat residual disease. Previous surveys have reported that 50–90% of institutions use such tissue-equivalent boluses [5–7]. The most common practice from a reported survey was a 5-mm-thick bolus on alternate days[7]. However, this method carries the risk of clinical error and possibility of not using the bolus on the set days. In addition, it requires two treatment plans that extend the duration, and induce further potential for error. In contrast, the use of daily boluses makes it easier to assess efficacy and toxicity since the daily dose is always the same; although this method increases the risk of severe skin toxicity [8]. As a basic experiment in our hospital, we measured the skin dose under the 1-, 2-, 3-, or 5-mm bolus on the chest wall using a phantom. We confirmed the previous finding that the mean surface dose of a 1-mm-thick daily bolus approximated that of a half-time 5-mm-thick bolus [9].

Thus, our hypothesis was a 1-mm-thick daily bolus would be a feasible regimen to reduce skin toxicity without the need for two treatment plans. Here we report the results of skin toxicity associated with PMRT using a 1-mm-thick daily bolus, as well as the skin dose using thermoluminescent dosimeters (TLDs; Toyo Medic Co., Ltd.; Tokyo, JP).

Methods
Patient selection

Patients (i) with pathologically confirmed breast cancer; (ii) requiring PMRT; (iii) aged 20 years and older; (iv) with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2; and (v) with no history of prior overlapping radiation were eligible for the study. Patients (i) with placement of a tissue expander, implant, or autologous tissue reconstruction; (ii) requiring boost irradiation for positive surgical margin; (iii) with severe comorbidity; and (iv) active double cancer were excluded from the study.

Study design

This single-center feasibility study evaluated the use of a 1-mm-thick daily tissue-equivalent bolus in patients who received PMRT using TLDs and skin toxicity assessment. As a pilot study, we aimed to recruit 20 participants for assessment of the surface dose and skin toxicity. Written informed consent was obtained from all patients. This prospective study was approved by the Institutional Review Board at The Juntendo University Hospital (approval number: 19–087), and was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000035773).

Treatment

Treatment plans were generated from a Toshiba Aquillion 16 LB computed tomography (CT) scanner (Toshiba Medical Systems Inc.; Otawara, JP), with 3-mm slices from the upper neck to the mid-abdomen. Three-dimensional treatment planning was performed using the Eclipse treatment planning system (Varian Medical Systems Inc.; Palo Alto, USA) TPS v. 13.6. All patients were treated with tangential 6-MV photon beams to the chest wall using the field-in-field technique, and a combination of anterior and posterior oblique 6- or 10-MV photon beams for the supraclavicular fossa. Patients with clinically positive internal mammary nodes were treated with wide tangential 6-MV photon beams to both the chest wall and internal mammary node area. Dose calculation was performed with an anisotropic analytical algorithm. Chest wall separation was measured between the sternal beam entry and the midaxillary line.

A 1-mm-thick tissue-equivalent Clearfit bolus (Fujidenolo Inc.; Aichi, JP) was placed over the chest wall, daily, for the entire course of PMRT (Fig. 1). The Clearfit bolus for the linac was colorless and soft, with a transparent finish. The daily radiotherapy fraction was 2.0 Gy according to the International Commission on Radiation Units and Measurements reference point, and was administered 5 days per week for a total dose of 50 Gy. Radiation plans were assessed by evaluating both isodose lines and the dose-volume histogram. A maximum hotspot of 115% was allowed.

In vivo dosimetry

In all patients, the surface dose to the skin under the bolus was measured within 5 days of beginning PMRT. TLDs were placed on the chest wall by one radiation oncologist, and measurements were taken at five sites as follows: Central, medial, lateral, superior, and inferior (Fig. 1). The first TLD was placed at the center of the field light. With this point as the center, each TLD was placed 3 to 5 cm to the medial, lateral, superior, and inferior. After irradiation, TLD was read out using a TLDR-1 (Toyo Medic CO., LTD., Tokyo, JP), and calculated using the DoseLab (Mobius medical system LP; Houston, USA). A 5 × 5 mm area of each TLD was used to determine the mean dose and standard error.

Skin toxicity

Skin toxicity was evaluated weekly during PMRT, and 1, 2, 4, and 12 weeks after completion of PMRT by two radiation oncologists. Radiation dermatitis was scored using the National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE) version 5.0 [10]. Standard skin care included nonfragrant moisturizing cream for skin dryness, and steroid cream in cases of excessive redness or inflammation.

Results

Patient characteristics

Of the 20 enrolled patients, one refused to participate; thus, 19 patients were enrolled from July 2019 to January 2020. All patients satisfied the eligibility criteria, and the patient characteristics are presented in Table 1. All patients completed the protocol treatment without interruptions, and the median treatment period was 35 (range, 32–40) days. The median follow-up from the start of PMRT was 32 (range, 19–54) weeks.
Table 1
Patient and tumor characteristics

| Patient and tumor characteristics | No. (%) |
|----------------------------------|---------|
| Median age, years (range)        | 59 (32–79) |
| Median height, cm (range)        | 155 (150–179) |
| Median weight, kg (range)        | 55 (43–74) |
| Median BMI (range)               | 21.8 (17.6–28.3) |
| History of smoking               |         |
| None                             | 14 (74) |
| Former smoker                    | 5 (26) |
| Diabetes                         |         |
| Yes                              | 1 (5) |
| No                               | 18 (95) |
| High blood pressure              |         |
| Yes                              | 4 (21) |
| No                               | 15 (79) |
| Cardiovascular disease           |         |
| Yes                              | 0 (0) |
| No                               | 19 (100) |
| Collagen disease                 |         |
| Yes                              | 0 (0) |
| No                               | 19 (100) |
| ECOG PS                          |         |
| 0                                | 18 (95) |
| 1                                | 1 (5) |
| Laterality                       |         |
| Left                             | 9 (47) |
| Right                            | 10 (53) |
| Clinical T stage                 |         |
| 1b                               | 1 (5) |
| 1c                               | 3 (16) |
| 2                                | 11 (58) |

Abbreviations: BMI: Body mass index, ECOG PS: Eastern Cooperative Oncology Group performance status, ER: Estrogen receptor, PR: Progesterone receptor. Values are number (percentage) or median (range).
### Patient and tumor characteristics

|                | No. (%) |
|----------------|---------|
| 3              | 3 (16)  |
| 4b             | 1 (5)   |
| **Clinical N stage** |         |
| 0              | 2 (11)  |
| 1              | 9 (47)  |
| 2a             | 3 (15)  |
| 2b             | 1 (5)   |
| 3a             | 2 (11)  |
| 3b             | 2 (11)  |
| **Clinical stage group** |     |
| IA             | 1 (5)   |
| IIA            | 4 (21)  |
| IIB            | 6 (32)  |
| IIIA           | 4 (21)  |
| IIIB           | 1 (5)   |
| IIIC           | 3 (16)  |
| **Pathologic T stage** |    |
| 0              | 4 (21)  |
| 1a             | 2 (11)  |
| 1c             | 4 (21)  |
| 2              | 6 (31)  |
| 3              | 2 (11)  |
| 4b             | 1 (5)   |
| **Pathologic N stage** |  |
| 0              | 3 (16)  |
| 1mi            | 2 (11)  |
| 1a             | 8 (42)  |
| 2a             | 5 (26)  |
| 3a             | 1 (5)   |
| **Pathologic stage group** | |

Abbreviations: BMI: Body mass index, ECOG PS: Eastern Cooperative Oncology Group performance status, ER: Estrogen receptor, PR: Progesterone receptor. Values are number (percentage) or median (range).
### Patient and tumor characteristics

| Characteristic                        | No. (%) |
|--------------------------------------|---------|
| **pCR**                              | 2 (11)  |
| **IA**                               | 1 (5)   |
| **IB**                               | 2 (11)  |
| **IIA**                              | 2 (11)  |
| **IIB**                              | 4 (21)  |
| **IIIA**                             | 7 (36)  |
| **IIIC**                             | 1 (5)   |
| **Receptor status**                  |         |
| ER positive                          | 14 (74) |
| ER negative                          | 5 (26)  |
| PR positive                          | 11 (58) |
| PR negative                          | 8 (42)  |
| HER2 positive                        | 12 (64) |
| HER2 negative                        | 7 (36)  |
| **Surgical margin**                  |         |
| Close                                | 4 (21)  |
| Negative                             | 15 (79) |
| **Chemotherapy delivery**            |         |
| Neoadjuvant                          | 10 (53) |
| Adjuvant                             | 8 (42)  |
| No                                   | 1 (5)   |
| **Chemotherapy delivery**            |         |
| Neoadjuvant                          | 10 (53) |
| Adjuvant                             | 8 (42)  |
| No                                   | 1 (5)   |
| **Hormone therapy**                  |         |
| Yes                                  | 14 (74) |
| No                                   | 5 (26)  |
| **Concurrent hormone therapy (yes)** |         |
| Anti-HER2 therapy (trastuzumab + pertuzumab) | 10 (53) |

Abbreviations: BMI: Body mass index, ECOG PS: Eastern Cooperative Oncology Group performance status, ER: Estrogen receptor, PR: Progesterone receptor. Values are number (percentage) or median (range).
| Patient and tumor characteristics | No. (%) |
|---------------------------------|---------|
| Yes                             | 8 (42)  |
| No                              | 11 (58) |
| Concurrent Anti-HER2 therapy (yes) | 7 (36) |
| Median chest wall separation, cm (range) | 19.0 (16.4–22.3) |

Abbreviations: BMI: Body mass index, ECOG PS: Eastern Cooperative Oncology Group performance status, ER: Estrogen receptor, PR: Progesterone receptor. Values are number (percentage) or median (range).

**In vivo dosimetry**

The TLDs measurements are shown in Table 2. In vivo dosimetry analysis revealed surface doses between 77% and 113% of the prescribed dose, with a mean of 92% of the prescribed radiation dose, and a standard deviation of 7% being delivered. The mean percentages of the prescribed radiation dose (standard deviation) for the central, medial, lateral, superior, and inferior TLDs were 93% (5%), 86% (5%), 98% (7%), 89% (5%), and 94% (5%), respectively.

| Mean % of prescribed dose (range; SD) |
|--------------------------------------|
| Central 93% (80–104%; 5%)           |
| Medial 86% (77–96%; 5%)             |
| Lateral 98% (88–113%; 7%)           |
| Superior 89% (80–100%; 5%)          |
| Inferior 94% (86–105%; 5%)          |
| Total 92% (77–113%; 7%)             |

Abbreviations: TLD: Thermoluminescent dosimeter, SD: Standard deviation.

**Skin toxicity**

All patients experienced radiation dermatitis during the treatment and follow-up period (Table 3, Fig. 2). Grade 2 dermatitis was found in 10 patients (53%) during, or within 2 weeks of PMRT. Grade 3 dermatitis (moist desquamation of the chest wall) was found in one patient (5%) 1 week after PMRT. All cases of Grade 2 and 3 dermatitis were improved 4 weeks after PMRT. There was no Grade 4 dermatitis.
Table 3
Maximum radiation dermatitis measured during the treatment and follow-up period

| Skin toxicity score                                                                 | No. (%) |
|-------------------------------------------------------------------------------------|---------|
| 0: No skin changes                                                                   | 0 (0)   |
| 1: Faint erythema or desquamation                                                    | 8 (42)  |
| 2: Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; and moderate edema | 10 (53) |
| 3: Moist desquamation in areas other than skin folds and creases, and bleeding induced by minor trauma or abrasion | 1 (5)   |
| 4: Life-threatening consequences: skin necrosis or ulceration of full thickness dermis, spontaneous bleeding from the involved site, skin graft indicated | 0 (0)   |

**Clinical outcomes**

No chest wall recurrences were observed during the treatment and follow-up period. One patient was found to have metastatic diseases to the bone and liver 4 weeks after PMRT.

**Discussion**

Dosimetric studies using a thinner daily bolus are limited in the existing literature.

In one study, Healy et al. reported the surface dose measurements of 16 patients using a daily 2-mm brass-mesh bolus for PMRT recorded by TLDs. They reported mean surface doses between 81% and 122% of the prescribed dose, with a mean of 99% of the prescribed radiation dose, and a standard deviation of 10% being delivered [11].

Another study by Ordonez-Sanz et al. reported comparison of surface doses among 3- and 5-mm-thick Superflab boluses, a 1-mm-thick brass-mesh bolus, and a half-time 10-mm-thick Vaseline bolus using a phantom recorded by TLDs. They reported that the mean surface dose was 68% of the prescription dose for no bolus, 100.7% for a Vaseline bolus, 97.7% for a 3-mm-thick Superflab bolus, and 91.6% for a brass-mesh bolus for their 6 MV plan [12]. Taken together, these results suggested that a brass-mesh bolus might be useful for PMRT; however, its use is restricted in our country because is not covered by insurance. The dosimetric outcomes of the present study are similar to those of previously published data, in that the mean surface dose was 92% (range, 77–113%) of the prescription dose. Therefore, it is conceivablea that a mean surface dose of approximately 90% of the prescribed dose (45 Gy in 25 fractions) was appropriate dose build up.

Our study demonstrated that the 1-mm-thick daily bolus is a safe regimen for PMRT with skin toxicity without treatment interruptions. In our study, only one (5%) patient was found to have Grade 3 skin toxicity, which is adequate compared to the published data of 12.2% with a daily 2-mm bolus, and 2.1% with no bolus [13, 14]. Indeed, Tieu et al. reported that PMRT was ceased early because of unacceptable skin toxicity in 17/143 (12%) of the whole chest wall daily 10-mm bolus patients, 2/88 (2%) of the parascar daily 10-mm bolus patients, and 1/23 (4%) of the no bolus patients. They concluded that the use of daily boluses may impact on early cessation of PMRT caused by skin toxicity, which may subsequently influence chest wall recurrence [8]. With regards to treatment completion with the
daily 1-mm bolus, it is possible that it will influence chest wall control. However, our finding that there were no cases of chest wall recurrence should be viewed with caution given the short follow-up period.

Maximum skin toxicity can occur 1 to 2 weeks after completion of PMRT [15]. However, previous prospective studies using a thinner daily bolus only reported skin toxicity during PMRT [11, 14]. We improved the research accuracy by evaluating skin toxicity 1, 2, 4, and 12 weeks after completion of PMRT in all patients.

In our study, 10 (53%) patients received PMRT concurrent with hormone therapy, and seven (36%) patients received PMRT concurrent with a combination of pertuzumab and trastuzumab. A recent meta-analysis concluded that PMRT concurrent with hormone therapy showed no significant difference in the incidence of radiation-induced acute skin toxicity compared to that of the sequential group [16]. However, the safety of PMRT concurrent with combination of pertuzumab and trastuzumab remains unclear [17]. At least, in our study, PMRT concurrent with a combination of pertuzumab and trastuzumab was well tolerated.

This study has several limitations. First, the sample size was small and the follow-up time was short. The follow-up period was used to determine acute skin toxicity, but it was not adequate to observe late toxicities. Second, although the use of the NCI-CTCAE skin toxicity scoring system attempts to standardize the quantification of skin toxicity, a small amount of subjectivity is required to assign scores; thus, assigned scores may vary between radiation oncologists. However, this difference is likely to be small given that skin toxicity was evaluated by two radiation oncologists in our study.

**Conclusions**

Our results confirmed the feasibility of using the 1-mm-thick daily bolus for PMRT, with appropriate dose buildup and acceptable skin toxicity without treatment interruptions.

This regimen could omit the clinical error and potential failure associated with using two treatment plans and bolus on alternate days while also making it easy to assess efficacy and toxicity since the daily dose is the same.

**Abbreviations**

CT: Computed tomography, ECOG PS: Eastern Cooperative Oncology Group performance status, NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events, PMRT: Postmastectomy radiotherapy, TLD: Thermoluminescent dosimeter

**Declarations**

**Acknowledgements**

Not applicable.

**Author contributions**

TK prepared the manuscript and conducted the literature search; TK reviewed and edited the manuscript; and TK, NS, CK, NH, MO, and KS reviewed the manuscript. All authors have read and approved the final manuscript.
Funding

No funding provided.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study has been approved by the ethics committee of The Juntendo University Hospital (approval number: 19-087). The study was conducted in accordance with the principles laid out in the Declaration of Helsinki and in accordance with the principles of Good Clinical Practice. Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Declarations

The authors declare that they have no competing interests.

Author details

1Department of Radiation Oncology, Juntendo University, Graduate School of Medicine, Tokyo, Japan
2Department of Radiology, Juntendo University Hospital, Tokyo, Japan

References

1. Feigenberg SJ, Price Mendenhall N, Benda RK, Morris CG: Postmastectomy radiotherapy: patterns of recurrence and long-term disease control using electrons. *International journal of radiation oncology, biology, physics* 2003, 56(3):716-725.
2. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet (London, England)* 2005, 366(9503):2087-2106.
3. McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T et al: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet (London, England)* 2014, 383(9935):2127-2135.
4. Cao L, Ou D, Shen KW, Cai G, Cai R, Xu F, Zhao SG, Xu C, Grellier Adedjouma N, Kirova YM et al: Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer. *Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique* 2018, **22**(1):38-44.

5. Vu TT, Pignol JP, Rakovitch E, Spayne J, Paszat L: Variability in radiation oncologists’ opinion on the indication of a bolus in post-mastectomy radiotherapy: an international survey. *Clinical oncology (Royal College of Radiologists (Great Britain))* 2007, **19**(2):115-119.

6. Blitzblau RC, Horton JK: Treatment planning technique in patients receiving postmastectomy radiation therapy. *Practical radiation oncology* 2013, **3**(4):241-248.

7. Mayadev J, Einck J, Elson S, Rugo H, Hwang S, Bold R, Daroui P, McCloskey S, Yashar C, Kim D et al: Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network. *Clinical breast cancer* 2015, **15**(1):43-47.

8. Tieu MT, Graham P, Browne L, Chin YS: The effect of adjuvant postmastectomy radiotherapy bolus technique on local recurrence. *International journal of radiation oncology, biology, physics* 2011, **81**(3):e165-171.

9. Kawamoto T, Shikama N, Kurokawa C, Haru N, Oshima M, Sasai K: Dosimetric assessment of bolus for postmastectomy radiotherapy. *Med Dosim* 2020.

10. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. [https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf](https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf).

11. Healy E, Anderson S, Cui J, Beckett L, Chen AM, Perks J, Stern R, Mayadev J: Skin dose effects of postmastectomy chest wall radiation therapy using brass mesh as an alternative to tissue equivalent bolus. *Practical radiation oncology* 2013, **3**(2):e45-53.

12. Ordones-Sanz C, Bowles S, Hirst A, MacDougall ND: A single plan solution to chest wall radiotherapy with bolus? *The British journal of radiology* 2014, **87**(1037):20140035.

13. Pignol JP, Vu TT, Mitera G, Bosnic S, Verkooijen HM, Truong P: Prospective evaluation of severe skin toxicity and pain during postmastectomy radiation therapy. *International journal of radiation oncology, biology, physics* 2015, **91**(1):157-164.

14. Das LC, Golden DW, Perevalova E, Wong AC, De Nardo K, Stepaniak C, Joyce DS, McCabe BP, Hasan Y, Chmura SJ et al: A feasibility study of 2-mm bolus for postmastectomy radiation therapy. *Practical radiation oncology* 2017, **7**(3):161-166.

15. Wright JL, Takita C, Reis IM, Zhao W, Lee E, Hu JJ: Racial variations in radiation-induced skin toxicity severity: data from a prospective cohort receiving postmastectomy radiation. *International journal of radiation oncology, biology, physics* 2014, **90**(2):335-343.

16. Li YF, Chang L, Li WH, Xiao MY, Wang Y, He WJ, Xia YX, Wang L, Chen Y: Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: A meta-analysis. *Breast* 2016, **27**:93-98.

17. Mignot F, Ajgal Z, Xu H, Geraud A, Chen JY, Mégnin-Chaten F, Kirova Y: Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review. *Radiother Oncol* 2017, **124**(2):190-199.

**Figures**
Figure 1

In vivo chest wall standard positions

Figure 2

Skin toxicity data Abbreviation: RT: Radiotherapy